SGLT2i, empagliflozin and canagliflozin, have been shown to reduce the incidence of major adverse CV events (MACE), all-cause mortality (ACM) and renal events in CV outcomes trials (CVOTs), with robust real-world evidence (RWE) suggesting class effect benefits. In the exenatide CVOT EXSCEL, 10% of patients took an SGLT2i with 5% use of dapagliflozin (DAPA). Effects of all SGLT2i, and DAPA alone, on MACE, ACM, and eGFR were analyzed in EXSCEL participants randomized to placebo.
SGLT2i overall, and DAPA alone, numerically decreased the MACE hazard ratio, and SGLT2i significantly reduced the ACM risk (Table) . The eGFR slope was improved significantly for SGLT2i overall and DAPA alone (Table) . 
